In cancer cells, lovastatin induced prostate cancer cell senescence by modulating RhoA expression33, and simvastatin increased reactive oxygen species production and promoted senescence via activation of the p53/p21 pathway in melanoma cells34. This evidence concerns the gene TP53 and prostate carcinoma.